U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H13F2N7O2S2
Molecular Weight 425.439
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of K-00546

SMILES

c1cc(c(c(c1)F)N=C(n2c(=N)nc(Nc3ccc(cc3)S(=O)(=O)N)[nH]2)S)F

InChI

InChIKey=ARIOBGGRZJITQX-UHFFFAOYSA-N
InChI=1S/C15H13F2N7O2S2/c16-10-2-1-3-11(17)12(10)21-15(27)24-13(18)22-14(23-24)20-8-4-6-9(7-5-8)28(19,25)26/h1-7H,(H,21,27)(H2,19,25,26)(H3,18,20,22,23)

HIDE SMILES / InChI

Molecular Formula C15H13F2N7O2S2
Molecular Weight 425.439
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including https://www.google.com/patents/WO2002057240A1 | https://www.ncbi.nlm.nih.gov/pubmed/25591119

3-Amino-N-(2,6-difluorophenyl)-5-(4-sulfamoylanilino)-1,2,4-triazole-1-carbothioamide (CDK1/2 INHIBITOR III) is potent inhibitor of Cyclin-dependent kinase 1/2 (IC50=0.6nM and 0,5nM) with marked antiproliferative activity.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
6.0E-4 µM [IC50]
5.0E-4 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities.
2005 Jun 30
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
Compound activity was evaluates in vitro inhibition of cell proliferation in various human tumor cells, including HeLa (cervical adenocarcinoma), HCT-116 (colon carcinoma), A375 (malignant melanoma), SK-OV-3 (ovarian adenocarcinoma), MDA-MB-231 (breast carcinoma), and PC-3 (prostate adenocarcinoma). Cells were trypsinized and counted and 3000-8000 cells were added to each well of a 96-well CytoStar tissue culture treated scintillating microplate. Cells were incubated for 24 hours in complete medium at 37 oC in an atmosphere containing 5% CO2. Next, 1  of compound 3n (CDK1/2 INHIBITOR III) in 100% DMSO was added to the wells of the plate. DMSO only was added to control wells. Cells were incubated for 24 more hours in complete medium at 37oC in an atmosphere containing 5% CO2.
Substance Class Chemical
Created
by admin
on Sat Jun 26 16:12:08 UTC 2021
Edited
by admin
on Sat Jun 26 16:12:08 UTC 2021
Record UNII
LFR1253W75
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
K-00546
Common Name English
CDK1/2 INHIBITOR III
Common Name English
5-AMINO-3-((4(AMINOSULFONYL)PHENYL)AMINO)-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE
Systematic Name English
1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE, 5-AMINO-3-((4-(AMINOSULFONYL)PHENYL)AMINO)-N-(2,6-DIFLUOROPHENYL)-
Systematic Name English
Code System Code Type Description
FDA UNII
LFR1253W75
Created by admin on Sat Jun 26 16:12:08 UTC 2021 , Edited by admin on Sat Jun 26 16:12:08 UTC 2021
PRIMARY
CAS
443798-47-8
Created by admin on Sat Jun 26 16:12:08 UTC 2021 , Edited by admin on Sat Jun 26 16:12:08 UTC 2021
PRIMARY
DRUG BANK
DB07664
Created by admin on Sat Jun 26 16:12:08 UTC 2021 , Edited by admin on Sat Jun 26 16:12:08 UTC 2021
PRIMARY
PUBCHEM
5330812
Created by admin on Sat Jun 26 16:12:08 UTC 2021 , Edited by admin on Sat Jun 26 16:12:08 UTC 2021
PRIMARY